1. Market Research
  2. > Respiratory Tract Infections – Pipeline Review, H1 2013

Respiratory Tract Infections – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 147 pages

Respiratory Tract Infections – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Respiratory Tract Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Respiratory Tract Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Tract Infections.
- A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Tract Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Respiratory Tract Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Respiratory Tract Infections - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Respiratory Tract Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Respiratory Tract Infections 9
Respiratory Tract Infections Therapeutics under Development by Companies 11
Respiratory Tract Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Respiratory Tract Infections Therapeutics - Products under Development by Companies 20
Respiratory Tract Infections Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Respiratory Tract Infections Therapeutics Development 24
Shionogi and Co., Ltd. 24
Sanofi-Aventis 25
GlaxoSmithKline plc 26
Daiichi Sankyo Company, Ltd 27
Targeted Genetics Corporation 28
Taisho Pharmaceutical Co., Ltd. 29
Takeda Pharmaceutical Company Limited 30
Nanotherapeutics, Inc. 31
Biological E. Limited 32
Rib-X Pharmaceuticals, Inc. 33
Nippon Shinyaku Co., Ltd. 34
Bayer AG 35
Zosano Pharma, Inc. 36
Insmed Incorporated 37
Dongwha Pharm Co., Ltd. 38
Green Cross Corporation 39
LG Life Sciences, Ltd 40
Panacea Biotec Limited 41
Creative Antibiotics Sweden AB 42
PolyMedix, Inc. 43
Functional Genetics, Inc. 44
MerLion Pharmaceuticals Pte Ltd 45
Novabiotics Ltd 46
Aridis Pharmaceuticals LLC 47
ProtAffin Biotechnologie AG 48
Destiny Pharma Ltd. 49
Kenta Biotech Ltd. 50
iBio, Inc. 51
Afexa Life Sciences Inc. 52
Indian Immunologicals Limited 53
Respiratory Tract Infections - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
amikacin - Drug Profile 60
ciprofloxacin - Drug Profile 62
amikacin liposomal - Drug Profile 64
amikacin liposomal - Drug Profile 66
gentamicin sulfate - Drug Profile 68
cidofovir - Drug Profile 69
RX-02 - Drug Profile 70
KBRV-201 - Drug Profile 71
CVT-E002 - Drug Profile 72
prulifloxacin - Drug Profile 74
zabofloxacin - Drug Profile 76
Act-HIB reconstituted with TRIPACEL - Drug Profile 78
PA-401 - Drug Profile 79
gallium citrate Ga 67 - Drug Profile 80
GSK-217744 - Drug Profile 81
DTP-HepB-Polio-Hib - Drug Profile 82
DTP-HepB-Polio-Hib - Drug Profile 84
DTaP-HepB - Drug Profile 86
DtwP-HB-Hib (liq) Vaccine - Drug Profile 87
LBVF-0101 - Drug Profile 88
DTwP-HepB Vaccine - Drug Profile 89
Anthrax Monoclonal Antibody - Drug Profile 90
GC-1107 - Drug Profile 91
Easysix - Drug Profile 93
finafloxacin - Drug Profile 95
TAK-361S - Drug Profile 97
Quadracel - Drug Profile 98
GSK-2140944 - Drug Profile 99
FGI-110 - Drug Profile 100
S-649266 - Drug Profile 101
Novarifyn - Drug Profile 102
Diptheria Vaccine - Drug Profile 103
PL-401 - Drug Profile 104
PL-402 - Drug Profile 105
6-O-(Heteroaryl-Isoxazolyl)Propynyl 2-Fluoro Ketolides - Drug Profile 106
Compound G-1 - Drug Profile 107
BioPhage-PR - Drug Profile 108
Tetrabhay DTwP-H Vaccine - Drug Profile 109
XF-70 - Drug Profile 110
DTwP-HBV-HIB Vaccine - Drug Profile 111
Virus Protease Inhibitors - Drug Profile 112
INP-11252 - Drug Profile 113
Compound-2a - Drug Profile 114
Cystic Fibrosis Phage - Drug Profile 115
GC-3111A - Drug Profile 116
Liposomal siRNAs - Drug Profile 117
Respiratory Tract Infections Therapeutics - Drug Profile Updates 118
Respiratory Tract Infections Therapeutics - Discontinued Products 134
Respiratory Tract Infections Therapeutics - Dormant Products 135
Respiratory Tract Infections - Product Development Milestones 137
Featured News and Press Releases 137
Appendix 143
Methodology 143
Coverage 143
Secondary Research 143
Primary Research 143
Expert Panel Validation 143
Contact Us 144
Disclaimer 144



List of Tables

Number of Products Under Development for Respiratory Tract Infections, H1 2013 12
Products under Development for Respiratory Tract Infections - Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 26
Shionogi and Co., Ltd., H1 2013 27
Sanofi-Aventis, H1 2013 28
GlaxoSmithKline plc, H1 2013 29
Daiichi Sankyo Company, Ltd, H1 2013 30
Targeted Genetics Corporation, H1 2013 31
Taisho Pharmaceutical Co., Ltd., H1 2013 32
Takeda Pharmaceutical Company Limited, H1 2013 33
Nanotherapeutics, Inc., H1 2013 34
Biological E. Limited, H1 2013 35
Rib-X Pharmaceuticals, Inc., H1 2013 36
Nippon Shinyaku Co., Ltd., H1 2013 37
Bayer AG, H1 2013 38
Zosano Pharma, Inc., H1 2013 39
Insmed Incorporated, H1 2013 40
Dongwha Pharm Co., Ltd., H1 2013 41
Green Cross Corporation, H1 2013 42
LG Life Sciences, Ltd, H1 2013 43
Panacea Biotec Limited, H1 2013 44
Creative Antibiotics Sweden AB, H1 2013 45
PolyMedix, Inc., H1 2013 46
Functional Genetics, Inc., H1 2013 47
MerLion Pharmaceuticals Pte Ltd, H1 2013 48
Novabiotics Ltd, H1 2013 49
Aridis Pharmaceuticals LLC, H1 2013 50
ProtAffin Biotechnologie AG, H1 2013 51
Destiny Pharma Ltd., H1 2013 52
Kenta Biotech Ltd., H1 2013 53
iBio, Inc., H1 2013 54
Afexa Life Sciences Inc., H1 2013 55
Assessment by Monotherapy Products, H1 2013 57
Assessment by Combination Products, H1 2013 58
Assessment by Stage and Route of Administration, H1 2013 60
Assessment by Stage and Molecule Type, H1 2013 62
Respiratory Tract Infections Therapeutics - Drug Profile Updates 121
Respiratory Tract Infections Therapeutics - Discontinued Products 137
Respiratory Tract Infections Therapeutics - Dormant Products 138



List of Figures

Number of Products under Development for Respiratory Tract Infections, H1 2013 12
Products under Development for Respiratory Tract Infections - Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 57
Assessment by Combination Products, H1 2013 58
Assessment by Route of Administration, H1 2013 59
Assessment by Stage and Route of Administration, H1 2013 60
Assessment by Molecule Type, H1 2013 61
Assessment by Stage and Molecule Type, H1 2013 62

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.